Combined angiotensin inhibition for the treatment of diabetic nephropathy

New England Journal of Medicine

Volumn 369, Issue 20, 2013, Pages 1892-1903

  Fried, Linda F ^a   Emanuele, Nicholas ^b,c   Zhang, Jane H ^d   Brophy, Mary ^f   Conner, Todd A ^g   Duckworth, William ^h,i   Leehey, David J ^b,c   McCullough, Peter A ^j,k,l,m,n   O'Connor, Theresa ^d   Palevsky, Paul M ^a   Reilly, Robert F ^o   Seliger, Stephen L ^p   Warren, Stuart R ^g   Watnick, Suzanne ^q   Peduzzi, Peter ^d,e   Guarino, Peter ^d  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b HINES VA HOSPITAL   (United States)

^c LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^d VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^e YALE UNIVERSITY   (United States)

^f BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g UNIVERSITY OF NEW MEXICO   (United States)

^h ARIZONA STATE UNIVERSITY   (United States)

ⁱ UNIVERSITY OF ARIZONA   (United States)

^j St John Providence Health System   (United States)

^k ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^l St John Macomb Oakland Hospital   (United States)

^m St John Macomb Oakland Hospital   (United States)

ⁿ PROVIDENCE HOSPITAL   (United States)

^o UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^p UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^q OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; PLACEBO;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; CEREBROVASCULAR ACCIDENT; COMBINATION CHEMOTHERAPY; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DOUBLE BLIND PROCEDURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG SAFETY; EARLY TERMINATION OF CLINICAL TRIAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HUMAN; HYPERKALEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RENAL SYSTEM PARAMETERS; URINARY ALBUMIN TO CREATININE RATIO;

EID: 84887467090     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1303154     Document Type: Article

References (20)

1. U.S. Renal Data System. USRDS 2012 annual data report: atlas of chronic kidney disease and end-stage renal disease in the United States. Bethesda, MD: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2012.
2. de Zeeuw D, Remuzzi G, Parving HH, et al. Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL. Kidney Int 2004;65:2309-20. (Pubitemid 38670018)
3. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861-9.
4. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 1993;329:1456-62. [Erratum, N Engl J Med 1993;330:152.] (Pubitemid 23335891)
5. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
6. de Zeeuw D. Albuminuria, not only a cardiovascular/renal risk marker, but also a target for treatment? Kidney Int Suppl 2004;92:S2-S6.
7. Kunz R, Friedrich C, Wolbers M, Mann JF. Meta-analysis: effect of monotherapy and combination therapy with inhibitors of the renin angiotensin system on proteinuria in renal disease. Ann Intern Med 2008;148:30-48. (Pubitemid 351688350)
8. Mann JF, Schmieder RE, McQueen M, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
9. The ONTARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
10. Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359-64. (Pubitemid 29355751)
11. Fried LF, Duckworth W, Zhang JH, et al. Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D). Clin J Am Soc Nephrol 2009;4:361-8.
12. National Kidney Foundation. KDOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;30:Suppl 1:S1-S266.
13. International Conference on Harmonisation. ICH Harmonised Tripartite Guideline E2A: guideline for clinical safety data management: definitions and standards for expedited reporting - consolidated guideline. Fed Regist 1995;60:11284-7.
14. Parving HH, Brenner BM, McMurray JJ, et al. Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-13.
15. Rahman M, Pressel S, Davis BR, et al. Renal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2005;165:936-46. (Pubitemid 40563242)
16. Cogan MG. Angiotensin II: a powerful controller of sodium transport in the early proximal tubule. Hypertension 1990;15:451-8. (Pubitemid 20148034)
17. Rose BD. Clinical physiology of acidbase and electrolyte disorders. 4th ed. New York: McGraw-Hill, 1994.
18. Schrier RW, Abdallah JG, Weinberger HH, Abraham WT. Therapy of heart failure. Kidney Int 2000;57:1418-25. (Pubitemid 30207901)
19. Siragy HM, Carey RM. Role of the intrarenal renin-angiotensin-aldosterone system in chronic kidney disease. Am J Nephrol 2010;31:541-50.
20. Chawla LS, Kimmel PL. Acute kidney injury and chronic kidney disease: an integrated clinical syndrome. Kidney Int 2012;82:516-24.